Skip to main navigation Skip to search Skip to main content

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)

  • Kasarskis, Edward (PI)

Grants and Contracts Details

StatusFinished
Effective start/end date10/20/20 → 6/15/22